Clinical trials technology company Science 37 went public during the Covid-19 pandemic, a time when drug developers readily embraced technologies that enable patients to participate in drug studies ...

RESEARCH TRIANGLE PARK, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the ...

RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today ...

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company ...

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite, announced today that it has acquired the life sciences platform ...

MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a ...

PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today the completion of a Phase 2b study for AOBiome, a clinical-stage life ...

The MarketWatch News Department was not involved in the creation of this content. MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical ...

Science 37 has been tapped to use its virtual clinical trial tech for phase 3 trials of Synlogic’s treatment for the rare genetic metabolic disorder phenylketonuria (PKU). Under the deal, Science 37’s ...

“After an extensive review of opportunities available to Science 37, we believe that eMed provides the greatest value to our stockholders, customers, patients, and employees” said David Coman, Chief ...